Skip to main content

Eli Lilly vs Regeneron: Strategic Comparison

Direct Answer

Eli Lilly is far bigger than Regeneron: $65.179 billion of 2025 revenue versus Regeneron's $14.343 billion, and a market capitalization near $1.06 trillion in September 2026 against Regeneron's roughly $75 billion. Lilly is also growing faster, with second-quarter 2026 revenue up 48% to $23.0 billion on Mounjaro and Zepbound demand, compared with Regeneron's 17% growth to $4.3 billion driven by Dupixent and EYLEA HD. Despite that size gap, the two companies had almost the same net margin in fiscal 2025, 31.7% for Lilly and 31.4% for Regeneron. By net income, Lilly's $20.640 billion was more than four and a half times Regeneron's $4.505 billion.

Eli Lilly, the first drugmaker to reach a $1 trillion market value on November 21, 2025, is roughly 4.5 times bigger than Regeneron by revenue, yet the two companies posted almost identical net margins in fiscal 2025: 31.7% for Lilly against 31.4% for Regeneron. Lilly, founded in 1876 in Indianapolis by Colonel Eli Lilly, has been led by Chair and CEO David A. Ricks since January 2017. Regeneron, founded 112 years later in 1988 in Tarrytown, New York, is still run by co-founder and CEO Leonard S. Schleifer alongside co-founder and Chief Scientific Officer George D. Yancopoulos. Lilly reported $65.179 billion in 2025 revenue and $20.640 billion in net income on about 50,000 employees, while Regeneron reported $14.343 billion in revenue and $4.505 billion in net income on 15,410 employees for the same fiscal year.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldEli Lilly and CompanyRegeneron Pharmaceuticals, Inc.
Latest annual revenue$65.2B (FY2025)$14.3B (FY2025)
Founded18761988
Employees50,00015,410
Market Cap$1.06T$75.0B
HeadquartersUnited StatesUnited States
Revenue / Employee$1.30M / employee$931k / employee
Valuation Multiple16.3x P/S5.2x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

Eli Lilly and Company Strategic Vector

FY2025 Revenue Baseline

Eli Lilly's corporate strategy focuses on expanding manufacturing capacity to meet soaring global demand for incretin therapeutics while advancing a diversified next-generation biopharmaceutical pipeline. Under Chief Executive Officer David Ricks, Lilly committed more than eighteen billion dollars to construct and expand state-of-the-art sterile injectable manufacturing campuses in Indiana, North Carolina, Ireland, and Germany to alleviate supply bottlenecks for Mounjaro and Zepbound. Concurrently, the company is pioneering oral, small-molecule GLP-1 receptor agonists (orforglipron) to provide convenient pill alternatives to weekly injections, alongside triple-hormone agonists (retatrutide) targeting GIP, GLP-1, and glucagon receptors for profound metabolic intervention. In neuroscience, the regulatory approval of Kisunla (donanemab) positions Lilly at the forefront of amyloid-clearing Alzheimer's therapies, creating another long-duration therapeutic franchise.

Productivity: $1.30M / employee

Regeneron Pharmaceuticals, Inc. Strategic Vector

FY2025 Revenue Baseline

Regeneron Pharmaceuticals, Inc.'s long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward pipeline broadening, where oncology, rare disease, gene therapy, gene editing, and cell therapy give Regeneron more shots beyond ophthalmology and Type 2 inflammation. Concurrently, the organization focuses on navigating market pressures around competition and reimbursement, addressing environments where biosimilars, branded rivals, payer pressure, and clinical setbacks can compress growth and margins. By maintaining disciplined capital allocation and operational rigor, Regeneron Pharmaceuticals, Inc. aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $931k / employee
Comparative Divergence: Lilly and Regeneron compete directly in atopic dermatitis, where Lilly's Ebglyss (lebrikizumab) won an expanded FDA-approved maintenance regimen of just six injections a year in 2026 aimed at taking share from the Sanofi-Regeneron drug Dupixent, though Ebglyss prescriptions remained small next to Dupixent's volume as of late 2026. Both companies are also racing to solve a side effect of the GLP-1 boom neither one created: muscle loss during rapid weight loss. Regeneron's anti-myostatin antibody trevogrumab, tested alongside Novo Nordisk's semaglutide, cut lean-mass loss by about half in the Phase 2 COURAGE trial reported October 1, 2026, while Lilly's own amylin-tirzepatide combination, EloraTZP, reported average weight loss of 23.3% in a trial disclosed September 30, 2026. Neither company has partnered its muscle-sparing science with the other, underscoring that Lilly and Regeneron are chasing the same obesity-adjacent opportunity as separate rivals rather than allies.

Eli Lilly vs Regeneron Market Share

Eli Lilly and Company market share
Eli Lilly and Company is one of the premier market leaders in Pharmaceuticals, obesity medicines, diabetes care, oncology, immunology, and neuroscience, commanding substantial market share and strong brand equity across its core geographic operating regions.
Regeneron Pharmaceuticals, Inc. market share
Regeneron is a leader in anti-VEGF retinal therapy through EYLEA and EYLEA HD, though it has lost share to Roche's Vabysmo and aflibercept biosimilars. Through Sanofi, Dupixent is one of the world's best-selling medicines, with $6.0 billion in global net sales in Q2 2026.

Quick Stats Comparison

MetricEli Lilly and CompanyRegeneron Pharmaceuticals, Inc.
Revenue$65.2B (FY2025)$14.3B (FY2025)
Founded18761988
HeadquartersIndianapolis, IndianaTarrytown, New York
Market Cap$1.06T$75.0B
Employees50,00015,410
Revenue / Employee$1.30M / employee$931k / employee
Valuation Multiple16.3x P/S5.2x P/S

Eli Lilly Revenue vs Regeneron Revenue — Year by Year

YearEli Lilly and CompanyRegeneron Pharmaceuticals, Inc.Higher reported revenue
2025$65.2B$14.3BEli Lilly and Company (approx. USD)
2024$45.0B$14.2BEli Lilly and Company (approx. USD)
2023$34.1B$13.1BEli Lilly and Company (approx. USD)
2022$28.5B$12.2BEli Lilly and Company (approx. USD)
2021$28.3B$16.1BEli Lilly and Company (approx. USD)

Business Model Breakdown

Overview: Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.

This in-depth comparison examines Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Regeneron Pharmaceuticals, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. is widest.

On the headline numbers, annual revenue is $65.2B (FY2025) for Eli Lilly and Company and $14.3B (FY2025) for Regeneron Pharmaceuticals, Inc., while their respective market capitalizations stand at $1.06T and $75.0B. Both Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Eli Lilly and Company: Eli Lilly is a 150-year-old Indianapolis pharmaceutical company that has become the world's largest drugmaker by market value. For most of its history it was best known for insulin and Prozac. Since 2022, tirzepatide, a dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, has transformed its scale, taking revenue from $28.5 billion in 2022 to $65.2 billion in 2025 and a guided $85-87 billion in 2026. The company is headquartered in Indianapolis, Indiana.

Regeneron Pharmaceuticals, Inc.: Regeneron is a Tarrytown, New York biotech that discovers, develops and manufactures its own biologic medicines. Its best-known products are EYLEA and EYLEA HD for retinal disease, Dupixent (with Sanofi) for eczema, asthma, COPD and other Type 2 inflammatory conditions, and Libtayo for cancer. Co-founders Leonard Schleifer (CEO) and George Yancopoulos (Chief Scientific Officer) still lead the company, which had about 15,400 employees at the end of 2025. Regeneron was founded in 1988 in New York City by Dr. Leonard Schleifer and Dr. George Yancopoulos, establishing its primary laboratories in Tarrytown, New York, and pioneering the proprietary VelociSuite genetics platform to build one of the world’s most scientifically productive biopharmaceutical giants.

Business Models: How Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. Make Money

Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Regeneron Pharmaceuticals, Inc..

Eli Lilly and Company business model: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. The company's business model is powered by targeted biologic therapies and synthetic peptide chemistry, generating revenue through patent-protected prescription drug sales to pharmaceutical wholesalers, hospital systems, and pharmacy benefit managers. Eli Lilly's revenue flywheel is led by its dual GIP/GLP-1 receptor agonist franchise—tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Beyond metabolic health, the company derives substantial recurring cash flows from oncology (Verzenio for HR+/HER2- breast cancer), immunology (Taltz, Omvoh), and neuroscience (Kisunla/donanemab for early symptomatic Alzheimer's disease). Revenue is reinvested at industry-leading rates into clinical trials, automated fill-finish manufacturing plants, and novel drug delivery platforms.

Regeneron Pharmaceuticals, Inc. business model: Regeneron makes money three ways. First, it records U.S. net product sales of its own medicines, mainly EYLEA HD and EYLEA for retinal disease, Libtayo in oncology, and smaller rare-disease products. Second, it earns collaboration revenue from Sanofi on Dupixent and Kevzara: Sanofi books global sales and the two companies share profits. Third, it shares ex-U.S. EYLEA profits with Bayer, which sells the drug outside the United States. The discovery engine behind all of this is VelociSuite, including VelocImmune mice that produce fully human antibodies.

Competitive Advantage: Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Regeneron Pharmaceuticals, Inc..

Eli Lilly and Company competitive advantage: Eli Lilly's formidable economic moat is founded on its multi-decade dominance in peptide synthesis, patent-protected intellectual property, and extensive global sterile manufacturing infrastructure. The development of tirzepatide established a first-in-class multi-receptor incretin platform that demonstrated superior glycemic control and weight reduction compared to single-hormone alternatives, granting Eli Lilly formidable pricing power and formulary tier positioning across private and public health insurance programs. Developing complex biologic therapies requires specialized high-speed parenterals, automated aseptic syringe filling lines, and rigorous peptide purification facilities that represent multi-billion-dollar barriers to entry. Lilly's patent portfolio creates statutory commercial exclusivity lasting through the next decade, while its clinical development velocity consistently brings breakthrough molecular entities from early discovery to regulatory approval ahead of historical pharmaceutical timelines.

Regeneron Pharmaceuticals, Inc. competitive advantage: Regeneron's edge is an in-house discovery platform (VelociSuite and VelocImmune) paired with the Regeneron Genetics Center's large human-sequencing dataset, which helps pick drug targets with genetic validation. Its two founders still run the company, so R&D priorities have stayed consistent for more than three decades, and it manufactures its own biologics in Rensselaer, New York and Limerick, Ireland.

Growth Strategy: Where Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. each plan to expand from here.

Eli Lilly and Company growth strategy: Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3. Lilly continues to build U.S. and European manufacturing capacity and uses acquisitions to add pipeline assets.

Regeneron Pharmaceuticals, Inc. growth strategy: Regeneron is defending ophthalmology with EYLEA HD (8 mg aflibercept, longer dosing intervals), widening Dupixent into new Type 2 inflammatory indications such as COPD, and building oncology and hematology around Libtayo and bispecifics such as linvoseltamab and odronextamab. It is also adding modalities through gene editing with Intellia, siRNA medicines with Alnylam, gene therapy from the Decibel deal and cell therapy through Regeneron Cell Medicines.

Financial Picture: Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.

A closer look at the financial trajectory of Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. rounds out the comparison.

Eli Lilly and Company: Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.

Regeneron Pharmaceuticals, Inc.: Regeneron's revenue rose from $4.86 billion in 2016 to $16.07 billion in 2021, inflated by COVID-19 antibody sales, then reset to $12.17 billion in 2022. It has since grown slowly: $13.12 billion in 2023, $14.20 billion in 2024 and $14.34 billion in 2025, as Dupixent gains offset lower original EYLEA sales. Growth picked up in 2026, with Q2 revenue up 17% to $4.3 billion, GAAP EPS of $12.23 and non-GAAP EPS of $14.29. Regeneron Pharmaceuticals, Inc. is a colossal American biotechnology company specializing in antibody therapeutics, sustaining a massive market valuation generally exceeding $100 billion.

Company-Specific SWOT Notes

Eli Lilly and Company

Strength

Lilly's tirzepatide franchise represents one of the most commercially successful pharmaceutical launches in history, with combined Mounjaro and Zepbound revenues of $36.5 billion in fiscal year 2025 and significant additional indication expansion in developmen

Strength

With more than 50 active molecules in clinical development and $13.3 billion invested in R&D in fiscal year 2025, Lilly's pipeline represents one of the most productive in the pharmaceutical industry.

Weakness

Despite a multi-billion-dollar manufacturing expansion program, Lilly's production capacity for tirzepatide and other injectable biologics has lagged the notable demand generated by commercial launches, resulting in drug shortages that have frustrated patients

Weakness

Tirzepatide, sold as Mounjaro and Zepbound, produced about 56% of Lilly's 2025 revenue and roughly 65% of Q2 2026 revenue.

Opportunity

The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the first small-molecule GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions.

Threat

The Inflation Reduction Act's Medicare drug price negotiation program, which allows the Centers for Medicare and Medicaid Services to directly negotiate prices for high-expenditure drugs, represents a structural threat to Lilly's revenue model in the United St

Regeneron Pharmaceuticals, Inc.

Strength

VelociSuite, genetic validation, and long-tenured scientific leadership give Regeneron a durable discovery engine.

Strength

Regeneron's foundational VelocImmune technology enables rapid generation of fully human monoclonal antibodies, creating blockbuster therapies like Dupixent (co-developed with Sanofi) and Eylea.

Weakness

EYLEA and Dupixent economics remain central, making franchise erosion and partner dynamics unusually important.

Weakness

The majority of consolidated operating income and royalty cash flows is tied to Dupixent and Eylea, leaving performance vulnerable to competitive ophthalmic and biologic alternatives.

Opportunity

Oncology, rare disease, gene therapy, gene editing, and cell therapy give Regeneron more shots beyond ophthalmology and Type 2 inflammation.

Threat

Biosimilars, branded rivals, payer pressure, and clinical setbacks can compress growth and margins.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScaleEli Lilly and Company$65.2B (FY2025) versus $14.3B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierEli Lilly and CompanyEli Lilly and Company was founded in 1876; Regeneron Pharmaceuticals, Inc. was founded in 1988.
Verdict

Comparison Takeaway: Eli Lilly vs Regeneron

Lilly's growth is concentrated in a single mechanism: tirzepatide-based Mounjaro and Zepbound made up roughly 56% of 2025 revenue, and the company is spending aggressively, $7.8 billion of 2025 capital expenditures, to keep up with demand that pushed 2026 guidance to $85-87 billion. Regeneron's revenue is split differently, between its own U.S. product sales (EYLEA HD, Libtayo) and collaboration profit-sharing with Sanofi on Dupixent and Bayer on ex-U.S. EYLEA, a structure that smooths swings but also capped 2025 growth at about 1%. That slower growth is one reason Regeneron was flagged as a value pick among large-cap pharma stocks in 2026 even as Lilly's shares pushed its market cap past $1 trillion. Lilly is the stronger pick for investors chasing growth tied to the obesity-drug boom; Regeneron is the stronger pick for investors wanting a founder-run, cash-generative platform business at a far lower valuation.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: Eli Lilly vs Regeneron

Is Eli Lilly bigger than Regeneron?

Yes. Lilly reported $65.179 billion of 2025 revenue, about 4.5 times Regeneron's $14.343 billion, and Lilly's roughly $1.06 trillion market capitalization in September 2026 was about 14 times Regeneron's near $75 billion. Lilly also employed about 50,000 people at the end of 2025 versus Regeneron's 15,410.

Does Eli Lilly or Regeneron have better profit margins?

They are nearly tied. Lilly's fiscal 2025 net margin was 31.7% ($20.640 billion of net income on $65.179 billion of revenue), while Regeneron's was 31.4% ($4.505 billion of net income on $14.343 billion of revenue), despite Lilly being more than four times larger.

Who are the CEOs of Eli Lilly and Regeneron?

David A. Ricks has been Eli Lilly's Chair and CEO since January 2017 (Chair since June 2017). Leonard S. Schleifer, M.D., Ph.D., co-founded Regeneron in 1988 and has run it as President and CEO ever since, alongside co-founder George D. Yancopoulos as Chief Scientific Officer.

Do Eli Lilly and Regeneron compete in eczema treatment?

Yes. Lilly's Ebglyss (lebrikizumab) and the Sanofi-Regeneron drug Dupixent (dupilumab) both block IL-13/IL-4 signaling in atopic dermatitis. Lilly won an expanded maintenance-dosing approval for Ebglyss in 2026, but Ebglyss prescriptions stayed a small fraction of Dupixent's volume, since Dupixent logged $6.0 billion of global quarterly sales in Q2 2026.

Which is the better stock, Eli Lilly or Regeneron?

It depends on the goal. Lilly offers faster growth, with Q2 2026 revenue up 48% to $23.0 billion and 2026 guidance of $85-87 billion tied to the obesity-drug boom, but trades at a much higher valuation after crossing $1 trillion in market value. Regeneron grew only about 1% in fiscal 2025 but was flagged as a top value pick among large-cap pharma stocks in 2026 for its lower valuation and founder-led platform.

Which company was founded first, Eli Lilly and Company or Regeneron Pharmaceuticals, Inc.?

Eli Lilly and Company was founded in 1876; Regeneron Pharmaceuticals, Inc. was founded in 1988.

What revenue did Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. report?

Eli Lilly and Company had $65.2B (FY2025), while Regeneron Pharmaceuticals, Inc. had $14.3B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. make money?

Eli Lilly and Company: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. Regeneron Pharmaceuticals, Inc.: Regeneron makes money three ways.

Which is better, Eli Lilly and Company or Regeneron Pharmaceuticals, Inc.?

There is no evidence-based single winner. Compare Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Eli Lilly is far bigger than Regeneron: $65.179 billion of 2025 revenue versus Regeneron's $14.343 billion, and a market capitalization near $1.06 trillion in September 2026 against Regeneron's roughly $75 billion. Lilly is also growing faster, with second-quarter 2026 revenue up 48% to $23.0 billion on Mounjaro and Zepbound demand, compared with Regeneron's 17% growth to $4.3 billion driven by Dupixent and EYLEA HD. Despite that size gap, the two companies had almost the same net margin in fiscal 2025, 31.7% for Lilly and 31.4% for Regeneron. By net income, Lilly's $20.640 billion was more than four and a half times Regeneron's $4.505 billion.

Verdict

Lilly's growth is concentrated in a single mechanism: tirzepatide-based Mounjaro and Zepbound made up roughly 56% of 2025 revenue, and the company is spending aggressively, $7.8 billion of 2025 capital expenditures, to keep up with demand that pushed 2026 guidance to $85-87 billion. Regeneron's revenue is split differently, between its own U.S. product sales (EYLEA HD, Libtayo) and collaboration profit-sharing with Sanofi on Dupixent and Bayer on ex-U.S. EYLEA, a structure that smooths swings but also capped 2025 growth at about 1%. That slower growth is one reason Regeneron was flagged as a value pick among large-cap pharma stocks in 2026 even as Lilly's shares pushed its market cap past $1 trillion. Lilly is the stronger pick for investors chasing growth tied to the obesity-drug boom; Regeneron is the stronger pick for investors wanting a founder-run, cash-generative platform business at a far lower valuation.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc. Comparison. from https://corpdigest.com/compare/eli-lilly-vs-regeneron

MLA Format

CorpDigest. "Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/eli-lilly-vs-regeneron.

Chicago Format

CorpDigest. "Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/eli-lilly-vs-regeneron.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.